JP2024525916A5 - - Google Patents
Info
- Publication number
- JP2024525916A5 JP2024525916A5 JP2024503724A JP2024503724A JP2024525916A5 JP 2024525916 A5 JP2024525916 A5 JP 2024525916A5 JP 2024503724 A JP2024503724 A JP 2024503724A JP 2024503724 A JP2024503724 A JP 2024503724A JP 2024525916 A5 JP2024525916 A5 JP 2024525916A5
- Authority
- JP
- Japan
- Prior art keywords
- cll
- cancer
- antibody
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210095142 | 2021-07-20 | ||
| KR10-2021-0095142 | 2021-07-20 | ||
| KR20210176638 | 2021-12-10 | ||
| KR10-2021-0176638 | 2021-12-10 | ||
| PCT/IB2022/056676 WO2023002390A1 (en) | 2021-07-20 | 2022-07-20 | Anti-cll-1 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525916A JP2024525916A (ja) | 2024-07-12 |
| JP2024525916A5 true JP2024525916A5 (enExample) | 2025-07-22 |
Family
ID=84979134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503724A Pending JP2024525916A (ja) | 2021-07-20 | 2022-07-20 | 抗ｃｌｌ－１抗体及びその用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250084158A1 (enExample) |
| EP (1) | EP4373856A4 (enExample) |
| JP (1) | JP2024525916A (enExample) |
| KR (1) | KR20240035504A (enExample) |
| WO (2) | WO2023002392A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024196678A2 (en) * | 2023-03-17 | 2024-09-26 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting cd3 and uses thereof |
| CN117964760B (zh) * | 2023-12-21 | 2024-09-03 | 四川大学华西医院 | 抗人cll1/cd3的双特异性抗体及其应用 |
| GB202411940D0 (en) * | 2024-08-13 | 2024-09-25 | Univ Exeter | Anti-CLEC12A Antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8536310B2 (en) * | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| TW201718647A (zh) * | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| WO2017010874A1 (en) * | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
| WO2017091615A1 (en) * | 2015-11-24 | 2017-06-01 | Cellerant Therapeutics, Inc. | Humanized anti-cll-1 antibodies |
| US11951129B2 (en) * | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
| CN111116753A (zh) * | 2018-10-30 | 2020-05-08 | 上海泰因生物技术有限公司 | 一种双特异性抗体的制备方法 |
| CN113366018A (zh) * | 2018-12-20 | 2021-09-07 | 美勒斯公司 | 用于治疗疾病的CLEC12AxCD3双特异性抗体和方法 |
| WO2021050857A1 (en) * | 2019-09-13 | 2021-03-18 | Memorial Sloan-Kettering Cancer Center | Anti-cd371 antibodies and uses thereof |
-
2022
- 2022-07-20 EP EP22845538.2A patent/EP4373856A4/en active Pending
- 2022-07-20 JP JP2024503724A patent/JP2024525916A/ja active Pending
- 2022-07-20 US US18/580,552 patent/US20250084158A1/en active Pending
- 2022-07-20 KR KR1020247003739A patent/KR20240035504A/ko active Pending
- 2022-07-20 WO PCT/IB2022/056679 patent/WO2023002392A1/en not_active Ceased
- 2022-07-20 WO PCT/IB2022/056676 patent/WO2023002390A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023522229A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2020152735A5 (enExample) | ||
| JP2022075818A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| JP2017500028A5 (enExample) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2017535257A5 (enExample) | ||
| JP2022512642A5 (enExample) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2017522871A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| JP2024534265A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2008537673A5 (enExample) | ||
| JP2024538669A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| JP2022526841A5 (enExample) | ||
| JP2025513745A5 (enExample) | ||
| JP2023549316A5 (enExample) | ||
| JP2025503229A5 (enExample) |